Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05114421
Title Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.